Synergy - the bonus that is achieved when things work together harmoniously. --Mark Twain
CEO and Director
Mr. Reutiman has 25 years of commercial experience in the medical device field, including leadership positions in sales and marketing, and sales management. He has significant expertise in commercializing products for minimally invasive interventional procedures, and participated in the development of many new technologies. Reutiman worked at Webster, TX-based IDEV Technologies from April 2012 to March 2014. Prior to that, from November 2006 to January 2012, he was Vice President of Sales and Marketing at San Clemente, CA-based ROX Medical, Inc. From March 2000 to December 2005 he was Vice President of Sales and Marketing at Mountain View, CA-based RITA Medical Systems. Before that Reutiman held sales management and representation positions at Guidant Corporation and Cordis Corporation. Reutiman has a bachelor of science degree in business from Colorado State University and an MBA from UC Irvine’s Paul Merage School of Business.
Kirk P. Seward, Ph.D.
Co-Founder, President, Chief Science and Technology Officer
Dr. Seward is the inventor of the Mercator Micro-Infusion Catheter and led its development from prototype through FDA 510(k) marketing clearance. Prior to co-founding Mercator MedSystems Dr. Seward was a staff principal investigator at Lawrence Livermore National Laboratory. He completed his doctoral studies in mechanical engineering at the University of California at Berkeley, and his masters and bachelors in mechanical engineering at MIT. He has authored more than 50 patent applications.
BOARD OF DIRECTORS
Charles Crocker is a principal of Crocker Capital, a private venture capital firm active in life sciences. He recently served as Chairman of the Board and CEO of BEI Technologies, Inc., a public, diversified technology company that he founded and was recently sold to Schneider Electric. He was Chairman, CEO, and founder of BEI Medical Systems, a public medical device company that was sold to Boston Scientific. He serves on the boards of Franklin Resources, Inc. and its subsidiaries (parent of the Franklin Templeton Funds) and Teledyne Technologies, Inc. He is Chair of the Franklin Compensation Committee. Mr. Crocker has been Chairman of the Board of Children’s Hospital in San Francisco, Chairman of the Hamlin School’s Board of Trustees, President of the Foundation of the Fine Arts Museums of San Francisco, and a Trustee of the Buck Center for Research in Aging. He currently serves as a Trustee of the Mary A. Crocker Trust. Mr. Crocker received his B.S. degree from Stanford University and an M.B.A from the University of California, Berkeley.
Neil P. Desai, Ph.D.
Dr. Desai has more than 20 years of experience in the research and development of novel therapeutics, drug delivery systems and biocompatible polymers. He is currently Vice President, Strategic Platforms at Celgene Corp. Prior to the acquisition by Celgene in Oct 2010, he was SVP, Global Research and Development, for Abraxis BioScience (ABI) where he was responsible for the development of ABI's proprietary product pipeline and intellectual property portfolio. This included the development of products from the early discovery phase through preclinical testing, late stage clinical studies and development for commercial manufacturing. Dr. Desai is a co-inventor of ABI's nab® tumor targeting nanotechnology platform which led to the first protein-based nanotechnology product (Abraxane®) to be approved by the FDA and regulatory agencies worldwide, for treatment of Metastatic Breast Cancer. At predecessor companies of ABI, VivoRx, Inc and VivoRx Pharmaceuticals, Inc., he worked on the early discovery and development of novel encapsulation systems for living cells and was part of the team that performed the world’s first successful encapsulated islet cell transplant in a diabetic patient. Dr. Desai is an inventor on over 100 patents, has authored or co-authored over 35 peer-reviewed publications, has made over 150 presentations at scientific meetings and has served on FDA, USP and European Union task forces and panels. He holds an M.S. and Ph.D. in Chemical Engineering from the University of Texas at Austin and a B.S. in Chemical Engineering from the University of Bombay.
Joel Kanter has served as President of Windy City, Inc., a privately held investment firm, since 1986. From 1989 - 1999, Mr. Kanter also served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (Nasdaq National Market: WNUT) that provided different forms of financing to small to large and early to late stage companies. The Company was sold to Tower Hill Capital Group in 1999 in a transaction valued at approximately $400 million. During that timeframe, Walnut concentrated on financing health care companies, and provided early stage financing to some 300 companies across the services (such as GranCare, which became the third largest long term care provider in the country and HealthcareCOMPARE which was the first utilization review company and the first nationwide PPO), device (such as Encore Medical, which was an orthopedic implant Company sold to Blackstone in 2007, and I-Flow, an infusion pump company that was sold to Kimberly Clark in 2009), life sciences (such as Pathogenesis and VaxGen), and consumer products (such as Plax Mouthwash and Sonicare toothbrushes). Mr. Kanter serves on the Board of Directors of several public companies including Dr. Tattoff, Inc., which is trying to become the first national provider of tattoo removal services; Medgenics, Inc., which is an Israeli biotechnology company; and WaferGen, which is engaged in the development, manufacturing and sales of state of the art systems for gene expression, genotyping and stem cell research for the life sciences, pharmaceutical drug discovery and development for biomarker discovery and diagnostic products industries, as well as a number of private concerns. Mr Kanter is also a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee of the Georgetown Day School in Washington, D.C., the current Board Chair of the Black Student Fund, an Executive Committee Member of the Kennedy Center’s National Committee on the Performing Arts, and serves on the Virginia Israel Advisory Board.
Ned Scheetz is Managing Director and founder of Aphelion Capital, a Healthcare Venture Fund with an investment emphasis in medical technology, consumer health & wellness, diagnostics and research tools. He has been an investor in numerous public and private medical technology companies for nearly two decades. Mr. Scheetz was a partner and managing director with Piper Jaffray Ventures and a Senior Analyst with Janus Capital. Board positions have included InSound Medical, OrthAlign, OrthoScan, SurgiQuest, Suros Surgical, and VasoNova while active investments have included Broncus/Asthmatx, Fox Hollow, Insulet, SurgiCount Medical, and Tria Beauty. Prior to beginning his investment career Mr. Scheetz worked in various product management and sales roles with a subsidiary of Eastman Kodak and Kraft General Foods. Mr. Scheetz is an advisory board member with the Center for Medical Device Innovation, and on the business advisory board of The Epilepsy Therapy Development Project. Mr. Scheetz is a graduate of Colby College, Duke University’s Fuqua School of Business, and was a post-graduate scholar at Oxford University. Mr. Scheetz holds the CFA designation.
Doug is the Managing Partner of Volcano Capital, LLC in New York. He is also a general partner of Summit Lifescience LP, a seed stage medical device fund located in Park City, Utah. Prior to Volcano Capital, he worked as an analyst at Outer Islands Capital, a hedge fund specializing in healthcare investments and led investor relations at Vital Signs, Inc. He is a board member of r4 Vascular Inc., Visionsense Ltd, Metascape and HydroCision.